Get the Stockscreener App
6.60
9.09%
0.55
After Hours:
6.64
0.04
+0.61%
Engene Holdings Inc stock is traded at $6.60, with a volume of 531.88K.
It is up +9.09% in the last 24 hours and down -5.44% over the past month.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
See More
Previous Close:
$6.05
Open:
$6.29
24h Volume:
531.88K
Relative Volume:
3.15
Market Cap:
$287.09M
Revenue:
-
Net Income/Loss:
$-103.21M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-26.70M
1W Performance:
+2.96%
1M Performance:
-5.44%
6M Performance:
-61.06%
1Y Performance:
+0.00%
1-Day Range:
$5.84
$6.67
1-Week Range:
$4.42
$7.5379
52-Week Range:
$4.42
$18.40
Engene Holdings Inc Stock (ENGN) Company Profile
Name
Engene Holdings Inc
Sector
Industry
Phone
(514) 332-4888
Address
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Engene Holdings Inc Stock (ENGN) Latest News
Perceptive Advisors LLC Sells 198,888 Shares of enGene Holdings Inc. (NASDAQ:ENGN) - MarketBeat
enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update - MarketBeat
Engene shares hold as Oppenheimer stands by $30 target - Investing.com South Africa
Engene shares hold as Oppenheimer stands by $30 target - Investing.com Australia
Engene shares hold as Oppenheimer stands by $30 target - Investing.com
Morgan Stanley maintains price target on Engene Holdings shares - Investing.com
EnGene Holdings Touches 52-Week Low After Drug Study Update - MarketWatch
The Future of enGene Holdings Inc: Analyzing ENGN - The InvestChronicle
enGene price target lowered to $17 from $26 at Leerink - TipRanks
Morgan Stanley maintains price target on Engene Holdings shares By Investing.com - Investing.com UK
SEC Form 424B3 filed by enGene Holdings Inc. - Quantisnow
enGene Holdings Excels in Bladder Cancer Treatment Trial - TipRanks
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort - Business Wire
(ENGN) Technical Data - Stock Traders Daily
enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Up 7,700.0% in September - Defense World
Engene stock poised for upside as key bladder cancer trial results nearOppenheimer - Investing.com India
enGene (NASDAQ:ENGN) Receives Outperform Rating from Oppenheimer - MarketBeat
Engene stock poised for upside as key bladder cancer trial results nearOppenheimer - Investing.com
Logos Global Management LP Purchases 400,000 Shares of enGene Holdings Inc. (NASDAQ:ENGN) - MarketBeat
Engene stock poised for upside as key bladder cancer trial results nearOppenheimer - Investing.com UK
enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
SR One Capital Management LP Makes New $4.72 Million Investment in enGene Holdings Inc. (NASDAQ:ENGN) - MarketBeat
enGene Holdings Inc. (ENGN): Wall Street Analysts Recommend This Canadian Stocks Right Now - Insider Monkey
enGene Holdings Inc. (ENGN): Wall Street Analysts Recommend This Canadian Stocks Right Now - Yahoo Finance
FY2024 EPS Estimates for enGene Holdings Inc. (NASDAQ:ENGN) Reduced by Analyst - MarketBeat
10 Best Canadian Stocks To Buy According to Wall Street Analysts - Insider Monkey
enGene (NASDAQ:ENGN) Announces Quarterly Earnings Results - MarketBeat
Morgan Stanley Reaffirms Overweight Rating for enGene (NASDAQ:ENGN) - MarketBeat
ENGNenGene Holdings Inc. Latest Stock News & Market Updates - StockTitan
EnGene Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2024 - Marketscreener.com
enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update - Business Wire
enGene Holdings Unveils Updated Corporate Strategy and Lead Program - TipRanks
How To Trade (ENGN) - Stock Traders Daily
EnGene to Participate in Upcoming Investor Conferences - Marketscreener.com
enGene to Participate in Upcoming Investor Conferences - Manchestertimes
enGene to Participate in Upcoming Investor Conferences - Business Wire
enGene Holdings Inc. (NASDAQ:ENGN) Receives $34.40 Consensus Target Price from Brokerages - MarketBeat
Oppenheimer Begins Coverage on enGene (NASDAQ:ENGN) - MarketBeat
Engene shares rise on Outperform rating, $30 target - Investing.com
enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Up 299.3% in August - MarketBeat
Financial Comparison: enGene (ENGN) versus Its Peers - Defense World
Comparing enGene (ENGN) and The Competition - Defense World
Critical Contrast: enGene (ENGN) & The Competition - Defense World
enGene (ENGN) and Its Competitors Financial Analysis - Defense World
enGene Holdings Inc. (NASDAQ:ENGN) Sees Large Decline in Short Interest - MarketBeat
Critical Contrast: enGene (ENGN) versus Its Competitors - Defense World
Head-To-Head Analysis: enGene (ENGN) & Its Rivals - Defense World
Critical Review: enGene (ENGN) & Its Peers - Defense World
Reviewing enGene (ENGN) & Its Competitors - Defense World
Head to Head Survey: enGene (ENGN) and The Competition - Defense World
Head to Head Review: enGene (ENGN) vs. Its Rivals - Defense World
Engene Holdings Inc Stock (ENGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):